Mersana Therapeutics

Mersana Therapeutics

Biotechnology Research

Cambridge, MA 12,182 followers

Our mission is to discover and develop life-changing antibody-drug conjugates (ADCs) for patients fighting cancer.

About us

At Mersana, we have a passion for advancing therapies to make a significant impact in the lives of people living with cancer. Mersana Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel antibody-drug conjugates (ADCs) and driven by the knowledge that patients are waiting for new treatment options. The company has developed proprietary cytotoxic (Dolasynthen) and immunostimulatory (Immunosynthen) ADC platforms that are generating a pipeline of wholly-owned and partnered product candidates with the potential to treat a range of cancers. Its pipeline includes XMT-1660, a Dolasynthen ADC targeting B7-H4, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2).

Industry
Biotechnology Research
Company size
51-200 employees
Headquarters
Cambridge, MA
Type
Public Company
Founded
2001
Specialties
cancer research, antibody drug conjugates, drug development, bioconjugation, and oncology

Locations

Employees at Mersana Therapeutics

Updates

Similar pages

Browse jobs

Funding

Mersana Therapeutics 12 total rounds

Last Round

Post IPO debt

US$ 100.0M

See more info on crunchbase